Drug giant Novartis is going after a $5 billion eye-drug market (NVS)
|11/11/2017||Posted by BusinessMediaguide.Com under General World News||
- Novartis on Friday showed that its drug, brolucizumab, worked as well as an existing drug that’s used to treat age-related macular degeneration.
- It’s a condition that affects more than 2 million people in the US.
- The hope is to get the drug approved to take on a roughly $5 billion market.
Novartis is gearing up to shake up a huge eye-drug market.
In data presented Friday at the American Academy of Opthamology annual conference, Novartis’ drug brolucizumab showed that it wasn’t any worse than Eylea, an existing drug to treat a condition called age-related macular degeneration. Novartis’ drug was read more >>>